MedTrace Logo

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT07247110 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-05-14

No results posted yet for this study

Summary

Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.

Conditions

  • Malignant Neoplasm

Interventions

DRUG

MK-4716

Oral administration

BIOLOGICAL

Pembrolizumab

Intravenous administration

BIOLOGICAL

Cetuximab

Intravenous administration

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-16
Primary Completion
2030-12-01
Completion
2030-12-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Chile
  • Israel
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07247110 on ClinicalTrials.gov